



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 138051

TO: Ben Sackey
Location: 5b31/5c18
Art Unit: 1626
Thursday, November 18, 2004

Case Serial Number: 10/612014

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Ben Sackey Examiner #: 673489 Date: 11/17/04
Art Unit: 1626 Phone Number 30 2-0704 Serial Number: 10/1626 (2014)
Mail Box and Bldg/Room Location: 5B31 Results Format Preferred (circle): PAPER DISK E-MAIL
SC:18

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Claim I Compound w/ specified (highlighted)
variables and elected species.

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher:	<u>Noble</u>	NA Sequence (#)	STN <u>621</u>
Searcher Phone #:		AA Sequence (#)	Dialog
Searcher Location:		Structure (#)	<u>2</u> Questel/Orbit
Date Searcher Picked Up:		Bibliographic	<u>✓</u> Dr.Link
Date Completed:		Litigation	Lexis/Nexis
Searcher Prep & Review Time:	<u>30</u>	Fulltext	Sequence Systems
Clerical Prep Time:		Patent Family	WWW/Internet
Online Time:	<u>60</u>	Other	Other (specify)

=> b reg
FILE 'REGISTRY' ENTERED AT 08:40:08 ON 18 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2004 HIGHEST RN 782447-68-1
DICTIONARY FILE UPDATES: 16 NOV 2004 HIGHEST RN 782447-68-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> d que stat 19
L7          STR
      10
      O
      ||
Cb—C—C—O—G1—C—O—NO2
 3   11    4   5   6   7   8   9
```

REP G1=(7-20) A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 3

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

```
L9          8 SEA FILE=REGISTRY SSS FUL L7
```


100.0% PROCESSED 2848 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

=> d ide 19 tot


```
L9  ANSWER 1 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN  676125-87-4 REGISTRY
CN  Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-[(2-
(nitrooxy)ethoxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)
MF  C20 H22 Cl2 N2 O7
SR  CA
LC  STN Files: CA, CAPLUS, CASREACT
DT.CA Caplus document type: Patent
RL.P Roles from patents: PREP (Preparation)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646511-50-4 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[(2-nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [[2-[(2-(Nitrooxy)ethyl)sulfonyl]ethyl]oxy]carbonylmethyl
 2-(6-methoxy-2-naphthyl)propanoate
 FS 3D CONCORD
 MF C20 H23 N O10 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-88-5 REGISTRY
 CN Ethanedioic acid, 2-[(2S)-2-(6-methoxy-2-naphthalenyl)-1-oxopropoxy]ethyl 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxyethyl 3-(nitrooxy)propyl ethane-1,2-dioate
 FS STEREOSEARCH
 MF C21 H23 N O10
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-17-0 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[(2-nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [[2-[(2-(Nitrooxy)ethyl)sulfonyl]ethyl]oxy]carbonylmethyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C20 H23 N O10 S

SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-09-0 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[(2-nitrooxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [N-Methyl-N-[[N-[(2-nitrooxy)ethyl]carbamoyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C21 H25 N3 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-05-6 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[(3-nitropropoxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [N-Methyl-N-[[[(3-nitropropyl)oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C22 H26 N2 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646509-99-1 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonylmethyl]carbamoylmethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C21 H24 N2 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

7
 L9 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 639067-65-5 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H33 N O6
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); USES (Uses)



Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que stat 144
L42 STR



VAR G1=CH2/12
REP G2=(7-20) A
NODE ATTRIBUTES:
NSPEC IS RC AT 1
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13


STEREO ATTRIBUTES: NONE
L44 7 SEA FILE=REGISTRY SSS FUL L42

100.0% PROCESSED 1933 ITERATIONS
SEARCH TIME: 00.00.02

7 ANSWERS

=> d ide 144 tot

L44 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 646511-50-4 REGISTRY
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[(2-nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [[[2-[(2-(Nitrooxy)ethyl)sulfonyl]ethyl]oxy]carbonylmethyl
2-(6-methoxy-2-naphthyl)propanoate
FS 3D CONCORD
MF C20 H23 N O10 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 646510-88-5 REGISTRY
CN Ethanedioic acid, 2-[(2S)-2-(6-methoxy-2-naphthalenyl)-1-oxopropoxy]ethyl 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxyethyl 3-(nitrooxy)propyl ethane-1,2-dioate
FS STEREOSEARCH
MF C21 H23 N O10
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES

(Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-17-0 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[(2-nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [[[2-[(2-nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonylmethyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C20 H23 N O10 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
 (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 646510-09-0 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[(2-nitrooxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN [N-Methyl-N-[(N-[(2-nitrooxy)ethyl]carbamoyl)methyl]carbamoyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate
 FS STEREOSEARCH
 MF C21 H25 N3 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
 (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 646510-05-6 REGISTRY
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[3-(nitrooxy)propoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [N-Methyl-N-[[[3-(nitrooxy)propyl]oxy]carbonylmethyl]carbamoylmethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
FS STEREOSEARCH
MF C22 H26 N2 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 646509-99-1 REGISTRY
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonylmethyl]carbamoylmethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
FS STEREOSEARCH
MF C21 H24 N2 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 639067-65-5 REGISTRY
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H33 N O6
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAPLUS document type: Patent
 RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 08:04:54 ON 18 NOV 2004)

FILE 'REGISTRY' ENTERED AT 08:04:59 ON 18 NOV 2004

L1 STR
 L2 0 L1
 L3 STR L1
 L4 0 L3
 L5 STR L3
 L6 0 L5
 L7 STR L5
 L8 0 L7
 L9 8 L7 FULL

FILE 'HCAPLUS' ENTERED AT 08:23:29 ON 18 NOV 2004

L10 1 US20040024057/PN

FILE 'REGISTRY' ENTERED AT 08:23:41 ON 18 NOV 2004

FILE 'HCAPLUS' ENTERED AT 08:23:42 ON 18 NOV 2004
 L11 TRA L10 1- RN : 265 TERMS

FILE 'REGISTRY' ENTERED AT 08:23:42 ON 18 NOV 2004
 L12 265 SEA L11
 L13 6 L9 AND L12

FILE 'HCAOLD' ENTERED AT 08:24:37 ON 18 NOV 2004
 L14 3 L9

FILE 'HCAOLD' ENTERED AT 08:24:43 ON 18 NOV 2004
 L15 0 L9

FILE 'HCAPLUS' ENTERED AT 08:24:47 ON 18 NOV 2004
 E EARL R/AU
 L16 55 E3-4,E8-10
 E EZAWA M/AU
 L17 15 E3-5
 E FANG X/AU
 L18 190 E3-18
 E FANG XINQIN/AU

L19 25 E3
 E GARVEY D/AU
 L20 127 E3,E8,E10,E12
 E GASTON R/AU
 L21 26 E3-4,E11-14
 E KNANAPURE S/AU
 E KHANAPURE S/AU
 L22 88 E4-7
 E LETTS L/AU
 L23 90 E4-5
 E LETTS G/AU
 L24 17 E3,E7-8
 E LIN C/AU
 L25 364 E3,E14
 E LIN CHIA/AU
 L26 14 E3,E17
 E RANATUNGE R/AU
 L27 10 E4-5
 E RICHARDSON S/AU
 L28 54 E3,E15
 E RICHARDSON STEWART/AU
 L29 38 E3-4
 E SCHROEDER J/AU
 L30 284 E3,E6-7
 E SCHROEDER JO/AU
 L31 34 E49,E51-52
 E STEVENSON C/AU
 L32 22 E3-4
 E STEVENSON CHERI/AU
 L33 2 E4
 E WEY S/AU
 L34 13 E3-4,E12
 L35 93 (NITROMED OR NITRO (1A) MED?)/CS, PA
 L36 1 L14 AND L16-35
 L37 2 L14 NOT L36

FILE 'REGISTRY' ENTERED AT 08:31:07 ON 18 NOV 2004
 L38 1 C21H24N2O9 AND L9

FILE 'HCAPLUS' ENTERED AT 08:31:38 ON 18 NOV 2004
 L39 1 L38
 L40 1 L39 AND L16-35
 L41 1 L36 OR L40

FILE 'REGISTRY', ENTERED AT 08:32:11 ON 18 NOV 2004
 L42 STR
 L43 0 L42
 L44 7 L42 FULL
 SAVE TEMP L44 SAC014F1/A

FILE 'HCAPLUS' ENTERED AT 08:37:05 ON 18 NOV 2004
 L45 2 L44

FILE 'HCAOLD' ENTERED AT 08:37:12 ON 18 NOV 2004
 L46 0 L44

FILE 'HCAPLUS' ENTERED AT 08:37:19 ON 18 NOV 2004
 L47 1 L45 AND L16-35
 L48 1 L45 NOT L47.

FILE 'STNGUIDE' ENTERED AT 08:37:35 ON 18 NOV 2004
 FILE 'HCAPLUS' ENTERED AT 08:38:40 ON 18 NOV 2004
 L49 1 L41 OR L47

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 08:40:54 ON 18 NOV 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2004 VOL 141 ISS 21
FILE LAST UPDATED: 17 Nov 2004 (20041117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

--> d all fhitstr 149 tot


L49 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:41217 HCAPLUS
 DN 140:111135
 ED Entered STN: 18 Jan 2004
 TI Preparation of nitrosated nonsteroidal antiinflammatory compounds
 IN Earl, Richard A.; Ezawa, Maiko; Fang, Xingqin
 ; Garvey, David S.; Gaston, Ricky D.; Khanapure,
 Subhash P.; Letts, Gordon L.; Lin, Chia-En;
 Ranatunge, Ramani R.; Richardson, Stewart K.;
 Schroeder, Joseph D.; Stevenson, Cheri A.; Wey,
 Shiow-Jyi
 PA Nitromed, Inc., USA
 SO PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004648	A2	20040115	WO 2003-US21026	20030703
	WO 2004004648	A3	20041028		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004024057	A1	20040205	US 2003-612014	20030703
PRAI	US 2002-393111P	P	20020703		
	US 2002-397979P	P	20020724		
	US 2002-418353P	P	20021016		
	US 2003-449798P	P	20030226		
	US 2003-456182P	P	20030321		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004004648	ICM	A61K
OS	MARPAT	140:111135	
GI			



AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared. For instance, naproxen is coupled to

2,2'-thiodiethanol (CH₂Cl₂, DMAP, EDCI) and treated with Ac₂O/HNO₃ at 0.degree. to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.

ST nitrosated nonsteroidal antiinflammatory pain prepn

IT Intestine, disease
 (Crohn's; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Antihistamines
 (H₂, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Pancreas, neoplasm
 (Zollinger-Ellison syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Carcinoma
 (adenocarcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Nose, disease
 (allergic rhinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Thromboxanes
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonists, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Infection
 (bacterial; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Skin, neoplasm
 (basal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Leukemia
 (basophilic; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Bronchi, disease
 (bronchitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Lip

Mouth
 (cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Nervous system, disease
 (central; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Uterus, neoplasm
 (cervix; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, neoplasm
 (colon; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 5-HT agonists

Analgesics

Antihistamines

Antitumor agents

Decongestants

Diuretics
 (combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Opioids
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Steroids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease
 (constipation; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder
 (dementia, multi-infarct; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder
 (dementia, vascular; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Animal tissue
 (deterioration; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Tendon
 (disease, tendinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Urogenital tract
 (disease; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Immunity
 Sexual behavior
 (disorder; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reticuloendothelial system
 (dysfunction, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Neoplasm
 (epithelial; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Fibrosis
 (from radiation therapy, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease
 (gastritis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Digestive tract, disease
 (gastroesophageal reflux; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease
 (gastroparesis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease
 (inflammatory; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Helicobacter pylori
 Platelet aggregation inhibitors
 (inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reperfusion
 (injury; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease
 (irritable bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Prostanoid receptors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (isoprostane, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Leukotriene receptors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (leukotriene B₄, antagonist, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mast cell
 (neoplasm, mastocytoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Thiols (organic), biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitrosated derivs., combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Anti-inflammatory agents
 (nonsteroidal, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Parturition
 (premature; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Alzheimer's disease
 Amnesia
 Angiogenesis
 Anti-Alzheimer's agents
 Anti-inflammatory agents
 Antiarthritics

Antiasthmatics
 Antimicrobial agents
 Autoimmune disease
 Bladder, neoplasm
 Brain, neoplasm
 Carcinoma
 Cardiovascular system, disease
 Digestive tract, disease
 Digestive tract, neoplasm
 Dyspepsia
 Esophagus, neoplasm
 Inflammation
 Liver, neoplasm
 Lung, neoplasm
 Mammary gland, neoplasm
 Neoplasm
 Neutrophil
 Ovary, neoplasm
 Pancreas, neoplasm
 Respiratory distress syndrome
 Skin, neoplasm
 Stomach, neoplasm
 Wound healing
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Transport proteins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (proton pump, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Kidney, neoplasm
 (renal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Mental disorder
 (senile psychosis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Shock (circulatory collapse)
 (septic; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Intestine, disease
 (short bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Intestine
 (small, cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Carcinoma
 (squamous cell; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Digestive tract, disease
 .ulcer, peptic; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT Intestine, disease
 .ulcerative colitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
 IT 50-78-2D, Aspirin, nitrosated derivs. 53-86-1D, Indomethacin, nitrosated derivs. 56-85-9, Glutamine, biological studies 56-87-1, Lysine, biological studies 61-68-7D, Mefenamic acid, nitrosated derivs. 65-45-2D, Salicylamide, nitrosated derivs. 70-26-8, Ornithine 74-79-3, L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated derivs. 89-57-6D, Mesalamine, nitrosated derivs. 156-86-5, L-Homoarginine 156-86-5D, L-Homoarginine, nitrosated derivs. 372-75-8, Citrulline 490-79-9D, Gentisic acid, nitrosated derivs. 530-78-9D, Flufenamic acid, nitrosated derivs. 552-94-3D, Salsalate, nitrosated derivs. 644-62-2D, Meclofenamic acid, nitrosated derivs. 959-10-4D, Xenbucin, nitrosated derivs. 1553-60-2D, Ibufenac, nitrosated derivs. 3583-64-0D, Bumadizon, nitrosated derivs. 4394-00-7D, Niflumic acid, nitrosated derivs. 5104-49-4D, Flurbiprofen, nitrosated derivs. 5728-52-9D, Felbinac, nitrosated derivs. 13710-19-5D, Tolfenamic acid, nitrosated derivs. 13799-03-6D, Protizinic acid, nitrosated derivs. 13993-65-2D, Metiazinic acid, nitrosated derivs. 15307-86-5D, Diclofenac, nitrosated derivs. 15687-27-1D, Ibuprofen, nitrosated derivs. 17969-20-9D, Fenclozic acid, nitrosated derivs. 18046-21-4D, Fentiazac, nitrosated derivs. 20168-99-4D, Cinmetacin, nitrosated derivs. 20187-55-7D, Bendazac, nitrosated derivs. 21256-18-8D, Oxaprozin, nitrosated derivs. 22071-15-4D, Ketoprofen, nitrosated derivs. 22204-53-1D, Naproxen, nitrosated derivs. 22494-42-4D, Diflunisal, nitrosated derivs. 23049-93-6D, Enfenamic acid, nitrosated derivs. 26171-23-3D, Tolmetin,

nitrosated derivs. 27470-51-5D, Suxibuzone, nitrosated derivs.
 29679-58-1D, Fenoprofen, nitrosated derivs. 31793-07-4D, Pirprofen,
 nitrosated derivs. 31842-01-0D, Indoprofen, nitrosated derivs.
 32808-51-8D, Bucloxic acid, nitrosated derivs. 33005-95-7D, Tiaprofenic
 acid, nitrosated derivs. 33369-31-2D, Zomepirac, nitrosated derivs.
 34148-01-1D, Clidanac, nitrosated derivs. 36330-85-5D, Fenbufen,
 nitrosated derivs. 38194-50-2D, Sulindac, nitrosated derivs.
 38677-85-9D, Flunixin, nitrosated derivs. 39718-89-3D, Alminoprofen,
 nitrosated derivs. 40828-46-4D, Suprofen, nitrosated derivs.
 41340-25-4D, Etadolac, nitrosated derivs. 42779-82-8D, Clopirac,
 nitrosated derivs. 50270-33-2D, Isofezolac, nitrosated derivs.
 51234-28-7D, Benoxaprofen, nitrosated derivs. 51579-82-9D, Amfenac,
 nitrosated derivs. 52549-17-4D, Pranoprofen, nitrosated derivs.
 53164-05-9D, Acemetacin, nitrosated derivs. 53597-27-6D, Fendosal,
 nitrosated derivs. 53716-49-7D, Carprofen, nitrosated derivs.
 53808-88-1D, Lonazolac, nitrosated derivs. 55453-87-7D, Isoxepac,
 nitrosated derivs. 55837-18-8D, Butibufen, nitrosated derivs.
 55843-86-2D, Miroprofen, nitrosated derivs. 56187-89-4D, Ximoprofen,
 nitrosated derivs. 66934-18-7D, Flunoxaprofen, nitrosated derivs.
 68767-14-6D, Loxoprofen, nitrosated derivs. 74103-06-3D, Ketorolac,
 nitrosated derivs. 74711-43-6D, Zaltoprofen, nitrosated derivs.
 78967-07-4D, Mofezolac, nitrosated derivs. 89796-99-6D, Aceclofenac,
 nitrosated derivs. 91714-94-2D, Bromfenac, nitrosated derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of naproxen-derived nitrosated
 antiinflammatory compds.)

IT 9002-04-4, Thrombin 9028-35-7, 3-Hydroxy-3-methylglutaryl coenzyme A
 reductase 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase
 90119-07-6, Leukotriene A4 hydrolase 125978-95-2, Nitric oxide synthase
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibitor, combination pharmaceutical; preparation of naproxen-derived
 nitrosated antiinflammatory compds.)

IT 9000-96-8, Arginase
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitor, combination pharmaceutical; preparation of naproxen-derived
 nitrosated antiinflammatory compds.)

IT 10102-43-9, Nitric oxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 183195-09-7P, [N-[2-(Nitrooxy)ethyl]carbamoyl]methyl 2-[2-[(2,6-
 dichlorophenyl)amino]phenyl]acetate 646509-36-6P, 2-[[2-
 (Nitrooxy)ethyl]thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-38-8P, 2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-39-9P 646509-41-3P, [2-[[2-
 (Nitrooxy)ethyl](4-nitrophenyl)amino]ethyl] (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-43-5P, (2R)-2,3-Bis(nitrooxy)propyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-45-7P 646509-47-9P
 646509-52-6P 646509-55-9P, [5-[(Nitrooxy)methyl]-1,3-dioxan-5-yl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-59-3P,
 2,2-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-63-9P, 3-[[4-(Nitrooxymethyl)phenyl]carbonyl]oxy-2-oxopropyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-67-3P 646509-71-9P,
 2-Nitro-3-(nitrooxy)-2-(nitrooxymethyl)propyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-75-3P, 2-[[N-[2-(Nitrooxy)ethyl]carbamoyl]oxy
]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-79-7P,
 3-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-84-4P, 4-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-88-8P, [N-Methyl-N-[2-
 (nitrooxy)ethyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-94-6P, [N-Ethyl-N-[2-(nitrooxy)ethyl]carbamoyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-98-0P,
 2-[4-(Nitrooxymethyl)piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-99-1P, [N-Methyl-N-[[[2-
 (nitrooxy)ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-05-6P, [N-Methyl-N-[[[3-
 (nitrooxy)propyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-09-0P, [N-Methyl-N-[[N-[2-
 (nitrooxy)ethyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-12-5P, [[[2-(Nitrooxy)ethyl]oxy]carbonyl]meth
 yl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-15-8P,
 [N-[3-(Nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-17-0P, [[[2-[(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-23-8P, [[[[1S,5S,2R,6R)-6-(Nitrooxy)-4,8-
 dioxabicyclo[3.3.0]octan-2-yl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-

naphthyl)propanoate 646510-27-2P, (2S)-2,3-Bis(nitrooxy)propyl
 (2S)-2-(6-methoxy-5-nitro-2-naphthyl)propanoate 646510-30-7P,
 (2S)-2-Hydroxy-3-(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646510-37-4P, (2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-39-6P, (2R)-2-Hydroxy-3-(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-41-0P,
 (2S)-2-(6-Methoxy-2-naphthyl)-N-[N-[2-(nitrooxy)ethyl]carbamoyl]methoxy]propanamide 646510-48-7P, 3-[2-[4-(Nitrooxymethyl)phenyl]acetoxy]-2-oxopropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-52-3P,
 2-[4-[2-(Nitrooxy)ethyl]piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-57-8P, 4-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-60-3P,
 2-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-62-5P, [N-Methyl-N-[3-(nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-67-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[2-[4-(nitrooxy)methyl]piperidin-1-yl]-2-oxoethoxy]propanamide 646510-69-2P,
 3-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-72-7P 646510-79-4P, 3-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]-2-methyl-2-[(nitrooxy)methyl]propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-83-0P,
 2-[4-[2-(Nitrooxy)ethoxy]phenoxy]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-88-5P, 2-[[2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl ethane-1,2-dioate 646510-93-2P, N-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-(nitrooxy)butanamide 646511-00-4P, 4-[[2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy] (2S,3S)-2,3-bis(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-02-6P,
 [(2S,3S)-2,3-Bis(nitrooxy)-4-hydroxybutyl] (2S)-2-[6-(methyloxy)-2-naphthyl]propanoate 646511-07-1P, 2-[[3-[(Nitrooxy)methyl]phenyl]carbonyl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-14-0P,
 (2R)-2-(Nitrooxy)-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-18-4P 646511-22-0P, [(1S,2S,5S,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-yl] 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 646511-23-1P, [(1S,2S,5S,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-yl] 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-25-3P,
 2-[(4-Methylphenyl)sulfonyl] [2-(nitrooxy)ethyl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-28-6P 646511-30-0P,
 (2R)-2,3-Bis(nitrooxy)propyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 646511-32-2P, (2S)-2,3-Bis(nitrooxy)propyl 2-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 646511-34-4P, (2S)-2,3-Bis(nitrooxy)propyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-36-6P, (2R)-2,3-Bis(nitrooxy)propyl 2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-37-7P, (2S)-2-(6-Methoxy-2-naphthyl)-1-[(4-nitrooxy)butyl]thio]propan-1-one 646511-41-3P, [N-Methyl-N-[2-(nitrooxy)ethyl]carbamoyl]methyl 2-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 646511-43-5P, [N-[2-(Nitrooxy)ethyl]carbamoyl]methyl 2-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 646511-47-9P, [[2-(Nitrooxy)ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate 646511-48-0P, [N-[3-(Nitrooxy)propyl]carbamoyl]methyl 2-(6-methoxy-2-naphthyl)propanoate 646511-50-4P, [[2-[(2-(Nitrooxy)ethyl)sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 53-86-1, Indomethacin 77-49-6, 2-Nitro-2-methyl-1,3-propanediol
 77-85-0, 1,1,1-Tris(hydroxymethyl)ethane 96-26-4, 1,3-Dihydroxyacetone
 99-06-9, 3-Hydroxybenzoic acid, reactions 99-96-7, 4-Hydroxybenzoic acid, reactions 103-76-4, 1-Piperazineethanol 104-38-1 109-83-1, Methyl[2-(hydroxy)ethyl]amine 109-94-4, Ethyl formate 110-73-6
 111-42-2, Diethanolamine, reactions 111-48-8, 2,2'-Thiodiethanol
 126-11-4, 2-Hydroxymethyl-2-nitro-1,3-propanediol 141-43-5, 2-Hydroxyethylamine, reactions 156-87-6, 3-Amino-1-propanol 350-46-9, 4-Fluoronitrobenzene 504-63-2, 1,3-Propanediol 524-38-9, N-Hydroxyphthalimide 540-51-2, 2-Bromoethanol 622-26-4, 2-(Piperidin-4-yl)ethanol 627-18-9, 3-Bromo-1-propanol 2319-57-5, L-Threitol 3084-40-0, Diethyl(hydroxymethyl)phosphonate 5292-43-3, tert-Butyl bromoacetate 6228-25-7, 1,3-Dioxane-5,5-dimethanol 6232-88-8, .alpha.-Bromo-p-toluic acid 6457-49-4, (Piperidin-4-yl)methanol 7146-67-0, N,N-Bis(2-hydroxyethyl)-p-toluenesulfonamide 13737-36-5, [4-(Bromomethyl)phenyl]acetic acid 14347-78-5,

((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 14970-83-3,
 4-Mercapto-1-butanol 15307-86-5, Diclofenac 16051-77-7, Isosorbide
 5-mononitrate 18162-48-6, tert-Butyldimethylsilyl chloride 22204-53-1
 22323-82-6, ((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 26159-34-2,
 (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt 26690-80-2,
 tert-Butyl N-(2-hydroxyethyl)carbamate 31719-77-4, 3-
 (Chloromethyl)benzoic acid 42865-19-0, 2-Bromoethyl isocyanate
 56552-80-8, (R)-(+)-3-Benzylxy-1,2-propanediol 58479-61-1,
 tert-Butylchlorodiphenylsilane 86940-98-9, ((4S)-2,2,4-Trimethyl-1,3-
 dioxolan-4-yl)methanol 136088-69-2 646509-51-5, [4-Nitro-1-(nitrooxy)-
 2-[(nitrooxy)methyl]butan-2-yl]amine 646510-25-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 4665-58-1P, [2-(Nitrooxy)ethyl]ammonium nitrate 18226-17-0P,
 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethanol 38483-29-3P
 42055-15-2P, 3-(Methylamino)propan-1-ol 49807-74-1P,
 N-(3-Hydroxypropyl)carboxamide 53164-05-9P, 2-[2-[1-[(4-
 Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetoxy]acetic acid
 54224-25-8P 56834-02-7P, tert-Butyl 2-aminoxyacetate 57561-39-4P
 65141-52-8P, [3-(Nitrooxy)propyl]amine nitrate 75302-98-6P,
 (tert-Butoxycarbonyl)methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-
 methylindol-3-yl]acetate 87426-50-4P, 2-Hydroxyethyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 97699-68-8P,
 2-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]acetic acid 100502-66-7P,
 3-(Nitrooxy)propan-1-ol 104963-92-0P 105566-73-2P, 2-Aminoethyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate hydrochloride 136404-13-2P
 139272-68-7P, (tert-Butoxycarbonyl)methyl 2-[2-[(2,6-
 dichlorophenyl)amino]phenyl]acetate 145459-16-1P, Methyl[2-
 (nitrooxy)ethyl]ammonium nitrate 154504-21-9P, (2S)-2,3-
 Bis(nitrooxy)propan-1-ol 161469-42-7P, 1-[(4S)-2,2-Dimethyl-1,3-
 dioxolan-4-yl)methoxy]-2,2-dimethyl-1,1-diphenyl-1-silapropene
 161469-43-8P, (2S)-3-[(2,2-Dimethyl-1,1-diphenyl-1-silapropyl)oxy]propane-
 1,2-diol 163385-71-5P, 2-(Nitrooxy)ethyl 4-hydroxybenzoate
 163385-76-0P, 2-(Nitrooxy)ethyl 2-hydroxybenzoate 163385-79-3P,
 2-(Nitrooxy)ethyl 3-hydroxybenzoate 258278-55-6P, 4-
 (Nitrooxymethyl)benzoic acid 364057-16-9P 364057-29-4P,
 2-[N-(tert-Butoxycarbonyl)-N-methylamino]ethyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 364057-30-7P, 2-(Methylamino)ethyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 382601-32-3P,
 (2R)-2,3-Bis(nitrooxy)propan-1-ol 385369-72-2P, 2-[(2-
 Hydroxyethyl)sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-37-7P, 2-[(2-Hydroxyethyl)thio]ethyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-40-2P 646509-42-4P, 2-[(2-Hydroxyethyl)(4-
 nitrophenyl)amino]ethyl 2-(6-methoxy-2-naphthyl)propanoate 646509-44-6P
 646509-46-8P, Phosphonomethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-57-1P, [5-(Hydroxymethyl)-1,3-dioxan-5-yl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-61-7P,
 3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-65-1P, 3-Hydroxy-2-oxopropyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-69-5P 646509-73-1P,
 3-Hydroxy-2-(hydroxymethyl)-2-nitropropyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646509-77-5P, 2-[[N-(2-Bromoethyl)carbamoyl]oxy]ethy-
 l (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-82-2P, 3-Hydroxyphenyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-86-6P, 4-Hydroxyphenyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-90-2P,
 (tert-Butoxycarbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 646509-97-9P, Ethyl[2-(nitrooxy)ethyl]ammonium nitrate 646510-00-1P,
 [N-[(tert-Butoxycarbonyl)methyl]-N-methylcarbamoyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-01-2P 646510-03-4P,
 [N-[[[(2-Hydroxyethyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-07-8P,
 [N-[[[(3-Hydroxypropyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-13-6P,
 [[[2-Hydroxyethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-19-2P, [[[2-(2-Hydroxyethylthio)ethyl]oxy]car-
 bonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-21-6P,
 [[[2-(2-Hydroxyethyl)sulfonyl]ethyl]oxy]carbonyl]methyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-32-9P,
 ((4R)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methyl (2S)-2-(6-methoxy-2-
 naphthyl)propanoate 646510-35-2P, [(2R)-2,3-Dihydroxy-2-methylpropyl]
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-44-3P, tert-Butyl
 2-[[[(2S)-2-(6-methoxy-2-naphthyl)propanoyl]amino]oxy]acetate
 646510-46-5P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]oxy]acetic
 acid 646510-50-1P, 2-[4-(Nitrooxymethyl)phenyl]acetic acid
 646510-54-5P 646510-65-8P, Methyl[3-(nitrooxy)propyl]amine
 646510-74-9P 646510-77-2P 646510-81-8P, 2-[[[(2S)-2-(6-Methoxy-2-

naphthyl)propanoyl]oxy]methyl]-3-hydroxy-2-methylpropyl
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-85-2P,
 2-[4-(2-Hydroxyethoxy)phenoxy]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-95-4P 646510-98-7P, N-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-hydroxybutanamide 646511-03-7P,
 (2S,3S)-1,4-Bis((1,1,2,2-tetramethyl-1-silapropyl)oxy)butane-2,3-diol 646511-04-8P, (2S,3S)-1,4-Bis((1,1,2,2-tetramethyl-1-silapropyl)oxy)-2,3-bis(nitrooxy)butane 646511-06-0P, (2S,3S)-2,3-Bis(nitrooxy)butane-1,4-diol 646511-09-3P, 3-[(Nitrooxy)methyl]benzoic acid 646511-11-7P,
 2-[(tert-Butoxycarbonyl)amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-15-1P, (2R)-2-Hydroxy-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-27-5P,
 2-[(2-Hydroxyethyl)[(4-methylphenyl)sulfonyl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-39-9P,
 (2S)-1-[(4-Hydroxybutyl)thio]-2-(6-methoxy-2-naphthyl)propan-1-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 51209-75-7, S-Nitroso-cysteine 56577-02-7, S-Nitroso-N-acetylcysteine 57564-91-7, S-Nitroso-glutathione 79032-48-7, S-Nitroso-N-acetylpenicillamine 122130-63-6, S-Nitroso-captopril 139427-42-2, S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 646509-99-1P, [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonyl]methyl carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

RN 646509-99-1 HCPLUS
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 137 tot

L37 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:267282 HCPLUS
 DN 140:287165
 ED Entered STN: 01 Apr 2004
 TI Manufacturing process for NO-donating compounds such as NO-donating diclofenac
 IN Andersson, Johan; Belli, Aldo; Cannata, Vincenzo; Hedberg, Martin; Palmgren, Andreas; Schuldei, Sigrid; Stroem, Marika; Villa, Marco
 PA AstraZeneca UK Limited, UK; AstraZeneca AB
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C201-00
 ICS C07C309-63; A61K031-216; A61P029-00; C07C211-55; C07C067-03;
 C07C303-28
 CC 25-8 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026808	A1	20040401	WO 2003-SE1465	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRAI SE 2002-2801 A 20020920
 SE 2003-1476 A 20030520

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004026808	ICM	C07C201-00
	ICS	C07C309-63; A61K031-216; A61P029-00; C07C211-55; C07C067-03; C07C303-28

OS CASREACT 140:287165; MARPAT 140:287165

AB NO-Donating compds. MLnAmCO2XONOp [M = residue of an NSAID, COX-1 inhibitor or COX-2 inhibitor; L = O, S, CO₂, (un)substituted CONH, NH, CO, CH₂, CH₂CO, CH₂CONH, CH₂CO₂; A = (un)substituted alkylene; X = carbon linker; m, n = 0-3; p = 1, 2] are prepared by treating MLnAmCO₂H with HOXOH, treating MLnAmCO₂XOH with RSO₂Cl [R = alkyl, (un)substituted Ph, CH₂Ph, halogen, CF₃, C₄F₉], and treating MLnAmCO₂XO₃SR with nitrate. A substantially crystalline form of 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate is reported.

ST nitrooxyalkyl ester NSAID COX inhibitor prepn nitric oxide donor

IT 10102-43-9, Nitrogen oxide (NO), biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

IT 174454-43-4P

RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

IT 108914-03-0P 120339-21-1P 354145-58-7P 409067-32-9P 676125-81-8P
 676125-85-2P 676125-90-9P 676125-93-2P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

IT 156661-01-7P 639067-51-9P 676125-87-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

IT 110-63-4, 1,4-Butanediol, reactions 111-46-6, Diethylene glycol, reactions 504-63-2, 1,3-Propanediol 15307-79-6, Diclofenac sodium 22161-81-5, (S)-Ketoprofen

RL: RCT (Reactant); RACT (Reactant or reagent)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Gianfranco, C; J Chem Soc Perkin Trans 1987, V1, P2637
- (2) Gianfranco, C; Tetrahedron Letters 1985, V41(7), P1385
- (3) Gianfranco, C; Tetrahedron Letters 1985, V26(28), P3369
- (4) Kiyoshi, K; Chem Pharm Bull 1990, V38(8), P2092
- (5) Nicox Limited; WO 9509831 A1 1995 HCPLUS
- (6) Nicox Limited; WO 9530641 A1 1995 HCPLUS
- (7) Ru, J; Synthesis 1994, P471
- (8) Union de Espanola de Explosivos S A; ES 2073995 A1 1995 HCPLUS

IT 676125-87-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (manufacturing process for NO-donating compds. such as NO-donating diclofenac)

RN 676125-87-4 HCPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-[2-(nitrooxy)ethoxy]ethoxy]ethyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:2666 HCAPLUS
 DN 140:65191
 ED Entered STN: 02 Jan 2004
 TI Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability
 IN Del Soldato, Piero; Santus, Giancarlo; Macelloni, Cristina
 PA Nicox S.A., Fr.
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-107
 ICS A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44; A61K031-4164; A61K031-4709
 CC 63-6 (Pharmaceuticals)

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000273	A1	20031231	WO 2003-EP6496	20030620
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI IT 2002-MI1392 A 20020625

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004000273	ICM	A61K009-107
	ICS	A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44; A61K031-4164; A61K031-4709

GI



I

AB The present invention relates to new pharmaceutical compns. for the administration of liquid drugs in solid oral forms, said compns. comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier. An emulsion was prepared containing I 100, Cremophor EL 50, Phospholipon 80H 50, Aerosil 200 100, and Explotab 100 g.
 ST oral pharmaceutical liq nitrate ester NSAID
 IT Glycerides, biological studies
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(C8-10, ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Quaternary ammonium compounds, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug delivery systems
(capsules; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Castor oil
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Anti-inflammatory agents
(nonsteroidal, nitrate esters; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug bioavailability
Surfactants
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Alcohols, biological studies
Bentonite, biological studies
Clays, biological studies
Glycerides, biological studies
Kaolin, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug delivery systems
(tablets; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT 56-81-5, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 67-68-5, Dmso, biological studies 68-12-2, Dmf, biological studies 71-23-8, 1-Propanol, biological studies 71-36-3, 1-Butanol, biological studies 78-83-1, Isobutyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 111-90-0 127-19-5, Dimethylacetamide 151-21-3, Sodium lauryl sulfate, biological studies 558-43-0, Isobutylene glycol 577-11-7, Dioctyl sodium sulfosuccinate 593-29-3, Potassium stearate 616-45-5, 2-Pyrrolidone 822-16-2, Sodium stearate 1309-42-8, Magnesium hydroxide 7631-86-9, Silica, biological studies 8044-71-1, Cetrimide 9002-92-0, Polyoxyethylene lauryl ether 9004-34-6, Cellulose, biological studies 9005-25-8, Starch, biological studies 9016-45-9, Polyoxyethylene nonylphenyl ether 12619-70-4, Cyclodextrin 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 21645-51-2, Aluminum hydroxide, biological studies 25265-75-2, Butylene glycol 63799-56-4, Labrafac 74791-03-0
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT 50-53-3, Chlorpromazine, biological studies 54-11-5, Nicotine 55-63-0, Nitroglycerin 77-38-3, Chlorphenoxamine 99-66-1, Valproic acid 104-31-4, Benzonatate 113-92-8, Chlorpheniramine maleate 461-78-9, Chlorphentermine 637-07-0, Clofibrate 156661-01-7 156970-83-1 158836-71-6 163133-43-5 164790-48-1 171781-26-3 174454-43-4 174454-49-0 175033-36-0 204633-00-1 301669-93-2 302543-79-9 311336-57-9 311336-59-1 311336-64-8 311336-66-0 352464-58-5 352464-62-1 497818-52-7 569371-19-3 639067-51-9 639067-52-0 639067-53-1 639067-54-2 639067-55-3 639067-56-4 639067-57-5 639067-58-6 639067-59-7 639067-60-0 639067-61-1 639067-62-2 639067-63-3 639067-64-4 639067-65-5 639067-66-6 639067-67-7 639067-68-8 639067-69-9 639067-70-2 639067-71-3 639067-72-4 639067-73-5 639067-75-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)


RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) AstraZeneca Ab; WO 0166087 A 2001 HCPLUS
- (2) AstraZeneca Ab; WO 0166088 A 2001 HCPLUS

(3) Nicox Sa; WO 0061537 A 2000 HCPLUS
IT 639067-65-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having
improved bioavailability)
RN 639067-65-5 HCPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl
ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 148 tot


L48 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:2666 HCAPLUS
DN 140:65191
ED Entered STN: 02 Jan 2004
TI Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability
IN Del Soldato, Piero; Santus, Giancarlo; Macelloni, Cristina
PA Nicox S.A., Fr.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-107
ICS A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44;
A61K031-4164; A61K031-4709
CC 63-6 (Pharmaceuticals)

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000273	A1	<20031231	WO 2003-EP6496	20030620
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 2002-MI1392 A 20020625
CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2004000273 ICM A61K009-107
ICS A61K031-216; A61K031-235; A61K031-407; A61K031-426;
A61K031-44; A61K031-4164; A61K031-4709

GI



- AB The present invention relates to new pharmaceutical compns. for the administration of liquid drugs in solid oral forms, said compns. comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier. An emulsion was prepared containing I 100, Cremophor EL 50, Phospholipon 80H 50, Aerosil 200 100, and Explotab 100 g.
- ST oral pharmaceutical liq nitrate ester NSAID
- IT Glycerides, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10, ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Quaternary ammonium compounds, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug delivery systems
(capsules; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Castor oil
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Anti-inflammatory agents
(nonsteroidal, nitrate esters; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug bioavailability
Surfactants
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Alcohols, biological studies
Bentonite, biological studies
Clays, biological studies
Glycerides, biological studies
Kaolin, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug delivery systems
(tablets; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT 56-81-5, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 67-68-5, Dmso, biological studies 68-12-2, Dmf, biological studies 71-23-8, 1-Propanol, biological studies 71-36-3, 1-Butanol, biological studies 78-83-1, Isobutyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 111-90-0 127-19-5, Dimethylacetamide 151-21-3, Sodium lauryl sulfate, biological studies 558-43-0, Isobutylene glycol 577-11-7, Dioctyl sodium sulfosuccinate 593-29-3, Potassium stearate 616-45-5, 2-Pyrrolidone 822-16-2, Sodium stearate 1309-42-8, Magnesium hydroxide 7631-86-9, Silica, biological studies 8044-71-1, Cetrimide 9002-92-0, Polyoxyethylene lauryl ether 9004-34-6, Cellulose, biological studies 9005-25-8, Starch, biological studies 9016-45-9, Polyoxyethylene nonylphenyl ether 12619-70-4, Cyclodextrin 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 21645-51-2, Aluminum hydroxide, biological studies 25265-75-2, Butylene glycol 63799-56-4, Labrafac 74791-03-0
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT 50-53-3, Chlorpromazine, biological studies 54-11-5, Nicotine 55-63-0, Nitroglycerin 77-38-3, Chlorphenoxamine 99-66-1, Valproic acid 104-31-4, Benzonatate 113-92-8, Chlorpheniramine maleate 461-78-9, Chlorphentermine 637-07-0, Clofibrate 156661-01-7 156970-83-1 158836-71-6 163133-43-5 164790-48-1 171781-26-3 174454-43-4 174454-49-0 175033-36-0 204633-00-1 301669-93-2 302543-79-9 311336-57-9 311336-59-1 311336-64-8 311336-66-0 352464-58-5 352464-62-1 497818-52-7 569371-19-3 639067-51-9 639067-52-0 639067-53-1 639067-54-2 639067-55-3 639067-56-4 639067-57-5 639067-58-6 639067-59-7 639067-60-0 639067-61-1 639067-62-2 639067-63-3 639067-64-4 639067-65-5 639067-66-6 639067-67-7 639067-68-8 639067-69-9 639067-70-2 639067-71-3 639067-72-4 639067-73-5 639067-75-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) AstraZeneca Ab; WO 0166087 A 2001 HCPLUS
- (2) AstraZeneca Ab; WO 0166088 A 2001 HCPLUS
- (3) Nicox Sa; WO 0061537 A 2000 HCPLUS

IT 639067-65-5


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RN 639067-65-5 HCPLUS

CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b home

FILE 'HOME' ENTERED AT 08:41:35 ON 18 NOV 2004

=>

=> d his

(FILE 'HOME' ENTERED AT 07:12:39 ON 18 NOV 2004)

L1 FILE 'HCAPLUS' ENTERED AT 07:12:49 ON 18 NOV 2004
1 US20040024057/PN

FILE 'REGISTRY' ENTERED AT 07:13:16 ON 18 NOV 2004

L2 FILE 'HCAPLUS' ENTERED AT 07:13:18 ON 18 NOV 2004
TRA L1 1- RN : 265 TERMS

L3 FILE 'REGISTRY' ENTERED AT 07:13:19 ON 18 NOV 2004
265 SEA L2

L4 FILE 'WPIX' ENTERED AT 07:13:23 ON 18 NOV 2004
1 US20040024057/PN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 07:13:44 ON 18 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2004 VOL 141 ISS 21
FILE LAST UPDATED: 17 Nov 2004 (20041117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 11

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41217 HCAPLUS
DN 140:111135
ED Entered STN: 18 Jan 2004
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds
IN Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Khanapure, Subhash P.; Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-Jyi
PA Nitromed, Inc., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2004004648	A2	20040115	WO 2003-US21026	20030703
WO 2004004648	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


US 2004024057	A1	20040205	US 2003-612014	20030703 <--
PRAI US 2002-393111P	P	20020703		
US 2002-397979P	P	20020724		
US 2002-418353P	P	20021016		
US 2003-449798P	P	20030226		
US 2003-456182P	P	20030321		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004004648	ICM	A61K
OS MARPAT 140:111135		

GI



- AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared For instance, naproxen is coupled to 2,2'-thiodiethanol (CH₂C₁₂, DMAP, EDCI) and treated with Ac₂O/HNO₃ at 0.degree. to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.
- ST nitrosated nonsteroidal antiinflammatory pain prep
- IT Intestine, disease
(Crohn's; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Antihistamines
(H₂, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Pancreas, neoplasm
(Zollinger-Ellison syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Carcinoma
(adenocarcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nose, disease
(allergic rhinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Thromboxanes
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Infection
(bacterial; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Skin, neoplasm
(basal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Leukemia
(basophilic; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Bronchi, disease
(bronchitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Lip
Mouth
(cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nervous system, disease
(central; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Uterus, neoplasm

(cervix; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Intestine, neoplasm
(colon; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT 5-HT agonists
Analgesics
Antihistamines
Antitumor agents
Decongestants
Diuretics
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Opioids
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Intestine, disease
(constipation; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Mental disorder
(dementia, multi-infarct; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Mental disorder
(dementia, vascular; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Animal tissue
(deterioration; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Tendon
(disease, tendinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Urogenital tract
(disease; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Immunity
Sexual behavior
(disorder; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Reticuloendothelial system
(dysfunction, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Neoplasm
(epithelial; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Fibrosis
(from radiation therapy, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Stomach, disease
(gastritis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Digestive tract, disease
(gastroesophageal reflux; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Stomach, disease
(gastroparesis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Intestine, disease
(inflammatory; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Helicobacter pylori
Platelet aggregation inhibitors
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Reperfusion
(injury; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Intestine, disease
(irritable bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT Prostanoid receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(isoprostane, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Leukotriene receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(leukotriene B₄, antagonist, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mast cell
(neoplasm, mastocytoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Thiols (organic), biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated derivs., combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Anti-inflammatory agents
(nonsteroidal, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Parturition
(premature; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Alzheimer's disease
Amnesia
Angiogenesis
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritis
Antiasthmatics
Antimicrobial agents
Autoimmune disease
Bladder, neoplasm
Brain, neoplasm
Carcinoma
Cardiovascular system, disease
Digestive tract, disease
Digestive tract, neoplasm
Dyspepsia
Esophagus, neoplasm
Inflammation
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Neutrophil
Ovary, neoplasm
Pancreas, neoplasm
Respiratory distress syndrome
Skin, neoplasm
Stomach, neoplasm
Wound healing
(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Transport proteins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proton pump, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Kidney, neoplasm
(renal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder
(senile psychosis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Shock (circulatory collapse)
(septic; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease
(short bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine
(small, cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Carcinoma
(squamous cell; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Digestive tract, disease
(ulcer, peptic; preparation of naproxen-derived nitrosated antiinflammatory

- compds.)
- IT Intestine, disease
(ulcerative colitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 50-78-2D, Aspirin, nitrosated derivs. 53-86-1D, Indomethacin, nitrosated derivs. 56-85-9, Glutamine, biological studies 56-87-1, Lysine, biological studies 61-68-7D, Mefenamic acid, nitrosated derivs. 65-45-2D, Salicylamide, nitrosated derivs. 70-26-8, Ornithine 74-79-3, L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated derivs. 89-57-6D, Mesalamine, nitrosated derivs. 156-86-5, L-Homoarginine 156-86-5D, L-Homoarginine, nitrosated derivs. 372-75-8, Citrulline 490-79-9D, Gentisic acid, nitrosated derivs. 530-78-9D, Flufenamic acid, nitrosated derivs. 552-94-3D, Salsalate, nitrosated derivs. 644-62-2D, Meclofenamic acid, nitrosated derivs. 959-10-4D, Xenbucin, nitrosated derivs. 1553-60-2D, Ibufenac, nitrosated derivs. 3583-64-0D, Bumadizon, nitrosated derivs. 4394-00-7D, Niflumic acid, nitrosated derivs. 5104-49-4D, Flurbiprofen, nitrosated derivs. 5728-52-9D, Felbinac, nitrosated derivs. 13710-19-5D, Tolfenamic acid, nitrosated derivs. 13799-03-6D, Protizinic acid, nitrosated derivs. 13993-65-2D, Metiazinic acid, nitrosated derivs. 15307-86-5D, Diclofenac, nitrosated derivs. 15687-27-1D, Ibuprofen, nitrosated derivs. 17969-20-9D, Fencloxic acid, nitrosated derivs. 18046-21-4D, Fentiazac, nitrosated derivs. 20168-99-4D, Cinmetacin, nitrosated derivs. 20187-55-7D, Bendazac, nitrosated derivs. 21256-18-8D, Oxaprozin, nitrosated derivs. 22071-15-4D, Ketoprofen, nitrosated derivs. 22204-53-1D, Naproxen, nitrosated derivs. 22494-42-4D, Diflunisal, nitrosated derivs. 23049-93-6D, Enfenamic acid, nitrosated derivs. 26171-23-3D, Tolmetin, nitrosated derivs. 27470-51-5D, Suxibuzone, nitrosated derivs. 29679-58-1D, Fenoprofen, nitrosated derivs. 31793-07-4D, Pirprofen, nitrosated derivs. 31842-01-0D, Indoprofen, nitrosated derivs. 32808-51-8D, Bucloxic acid, nitrosated derivs. 33005-95-7D, Tiaprofenic acid, nitrosated derivs. 33369-31-2D, Zomepirac, nitrosated derivs. 34148-01-1D, Clidanac, nitrosated derivs. 36330-85-5D, Fenbufen, nitrosated derivs. 38194-50-2D, Sulindac, nitrosated derivs. 38677-85-9D, Flunixin, nitrosated derivs. 39718-89-3D, Alminoprofen, nitrosated derivs. 40828-46-4D, Suprofen, nitrosated derivs. 41340-25-4D, Etodolac, nitrosated derivs. 42779-82-8D, Clopirac, nitrosated derivs. 50270-33-2D, Isofezolac, nitrosated derivs. 51234-28-7D, Benoxaprofen, nitrosated derivs. 51579-82-9D, Amfenac, nitrosated derivs. 52549-17-4D, Pranoprofen, nitrosated derivs. 53164-05-9D, Acemetacin, nitrosated derivs. 53597-27-6D, Fendosal, nitrosated derivs. 53716-49-7D, Carprofen, nitrosated derivs. 53808-88-1D, Lonazolac, nitrosated derivs. 55453-87-7D, Isoxepac, nitrosated derivs. 55837-18-8D, Butibufen, nitrosated derivs. 55843-86-2D, Miroprofen, nitrosated derivs. 56187-89-4D, Ximoprofen, nitrosated derivs. 66934-18-7D, Flunoxaprofen, nitrosated derivs. 68767-14-6D, Loxoprofen, nitrosated derivs. 74103-06-3D, Ketorolac, nitrosated derivs. 74711-43-6D, Zaltoprofen, nitrosated derivs. 78967-07-4D, Mofezolac, nitrosated derivs. 89796-99-6D, Aceclofenac, nitrosated derivs. 91714-94-2D, Bromfenac, nitrosated derivs.
- RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 9002-04-4, Thrombin 9028-35-7, 3-Hydroxy-3-methylglutaryl coenzyme A reductase 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase 90119-07-6, Leukotriene A4 hydrolase 125978-95-2, Nitric oxide synthase RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 9000-96-8, Arginase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 183195-09-7P, [N-[2-(Nitrooxy)ethyl]carbamoyl]methyl 2-[(2,6-dichlorophenyl)amino]phenylacetate 646509-36-6P, 2-[[2-(Nitrooxy)ethyl]thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-38-8P, 2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-39-9P, 646509-41-3P, [2-[[2-(Nitrooxy)ethyl](4-nitrophenyl)amino]ethyl] (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-43-5P, (2R)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-45-7P, 646509-47-9P 646509-52-6P, 646509-55-9P, [5-[(Nitrooxy)methyl]-1,3-dioxan-5-yl]methyl

(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-59-3P,
2,2-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646509-63-9P, 3-[[4-(Nitrooxymethyl)phenyl]carbonyl]oxy]-2-oxopropyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-67-3P 646509-71-9P,
2-Nitro-3-(nitrooxy)-2-(nitrooxymethyl)propyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646509-75-3P, 2-[N-[2-(Nitrooxy)ethyl]carbamoyl]oxy
ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-79-7P,
3-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646509-84-4P, 4-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646509-88-8P, [N-Methyl-N-[2-
(nitrooxy)ethyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646509-94-6P, [N-Ethyl-N-[2-(nitrooxy)ethyl]carbamoyl]methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-98-0P,
2-[4-(Nitrooxymethyl)piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646509-99-1P, [N-Methyl-N-[[[2-
(nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl)methyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-05-6P, [N-Methyl-N-[[[3-
(nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl)methyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-09-0P, [N-Methyl-N-[N-[2-
(nitrooxy)ethyl]carbamoyl]methyl]carbamoyl)methyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-12-5P, [[2-(Nitrooxy)ethyl]oxy]carbonyl)methyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-15-8P,
[N-[3-(Nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-17-0P, [[2-[2-(Nitrooxy)ethyl]sulfonyl]ethy
l]oxy]carbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646510-23-8P, [[[1S,5S,2R,6R]-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-
2-yl]oxy]carbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646510-27-2P, (2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-5-nitro-2-
naphthyl)propanoate 646510-30-7P, (2S)-2-Hydroxy-3-(nitrooxy)propyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-37-4P,
(2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
646510-39-6P, (2R)-2-Hydroxy-3-(nitrooxy)propyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-41-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[N-[2-
(nitrooxy)ethyl]carbamoyl]methoxy]propanamide 646510-48-7P,
3-[2-[4-(Nitrooxymethyl)phenyl]acetoxy]-2-oxopropyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-52-3P, 2-[4-[2-(Nitrooxy)ethyl]piperidin-1-
yl]-2-oxoethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-57-8P,
4-[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-60-3P, 2-[[2-(Nitrooxy)ethyl]oxy]carbonyl]ph
enyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-62-5P,
[N-Methyl-N-[3-(nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-67-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[2-[4-
[(nitrooxy)methyl]piperidin-1-yl]-2-oxethoxy]propanamide 646510-69-2P,
3-[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-72-7P 646510-79-4P, 3-[(2S)-2-(6-Methoxy-2-
naphthyl)propanoyl]oxy]-2-methyl-2-[(nitrooxy)methyl]propyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-83-0P,
2-[4-(2-(Nitrooxy)ethoxy]phenoxyethyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646510-88-5P, 2-[(2S)-2-(6-Methoxy-2-
naphthyl)propanoyl]oxyethyl 3-(nitrooxy)propyl ethane-1,2-dioate
646510-93-2P, N-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-
(nitrooxy)butanamide 646511-00-4P, 4-[(2S)-2-(6-Methoxy-2-
naphthyl)propanoyl]oxy] (2S,3S)-2,3-bis(nitrooxy)butyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-02-6P,
[(2S,3S)-2,3-Bis(nitrooxy)-4-hydroxybutyl] (2S)-2-[6-(methyloxy)-2-
naphthyl]propanoate 646511-07-1P, 2-[[3-[(Nitrooxy)methyl]phenyl]carbon
yl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-14-0P,
(2R)-2-(Nitrooxy)-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-
naphthyl)propanoate 646511-18-4P 646511-22-0P, [(1S,2S,5S,6R)-6-
(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-yl] 2-[1-[(4-
chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate
646511-23-1P, [(1S,2S,5S,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-
y1] 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-25-3P,
2-[(4-Methylphenyl)sulfonyl] [2-(nitrooxy)ethyl]amino]ethyl
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-28-6P 646511-30-0P,
(2R)-2,3-Bis(nitrooxy)propyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-
methylindol-3-yl]acetate 646511-32-2P, (2S)-2,3-Bis(nitrooxy)propyl
2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate
646511-34-4P, (2S)-2,3-Bis(nitrooxy)propyl 2-[2-[(2,6-
dichlorophenyl)amino]phenyl]acetate 646511-36-6P, (2R)-2,3-
Bis(nitrooxy)propyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate
646511-37-7P, (2S)-2-(6-Methoxy-2-naphthyl)-1-[(4-
(nitrooxy)butyl]thio]propan-1-one 646511-41-3P, [N-Methyl-N-[2-
(nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-
2-methylindol-3-yl]acetate 646511-43-5P, [N-[2-
(Nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-

2-methylindol-3-yl]acetate 646511-47-9P, [[2-(Nitrooxy)ethyl]oxy]carbonylmethyl 2-(6-methoxy-2-naphthyl)propanoate
 646511-48-0P, [N-[3-(Nitrooxy)propyl]carbamoyl)methyl 2-(6-methoxy-2-naphthyl)propanoate 646511-50-4P, [[2-[(2-(Nitrooxy)ethyl)sulfonyl]ethyl]oxy]carbonylmethyl 2-(6-methoxy-2-naphthyl)propanoate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 53-86-1, Indomethacin 77-49-6, 2-Nitro-2-methyl-1,3-propanediol
 77-85-0, 1,1,1-Tris(hydroxymethyl)ethane 96-26-4, 1,3-Dihydroxyacetone
 99-06-9, 3-Hydroxybenzoic acid, reactions 99-96-7, 4-Hydroxybenzoic acid, reactions 103-76-4, 1-Piperazineethanol 104-38-1 109-83-1, Methyl[2-(hydroxy)ethyl]amine 109-94-4, Ethyl formate 110-73-6
 111-42-2, Diethanolamine, reactions 111-48-8, 2,2'-Thiodiethanol 126-11-4, 2-Hydroxymethyl-2-nitro-1,3-propanediol 141-43-5, 2-Hydroxyethylamine, reactions 156-87-6, 3-Amino-1-propanol 350-46-9, 4-Fluoronitrobenzene 504-63-2, 1,3-Propanediol 524-38-9, N-Hydroxyphthalimide 540-51-2, 2-Bromoethanol 622-26-4, 2-(Piperidin-4-yl)ethanol 627-18-9, 3-Bromo-1-propanol 2319-57-5, L-Threitol 3084-40-0, Diethyl(hydroxymethyl)phosphonate 5292-43-3, tert-Butyl bromoacetate 6228-25-7, 1,3-Dioxane-5,5-dimethanol 6232-88-8, .alpha.-Bromo-p-toluic acid 6457-49-4, (Piperidin-4-yl)methanol 7146-67-0, N,N-Bis(2-hydroxyethyl)-p-toluenesulfonamide 13737-36-5, [4-(Bromomethyl)phenyl]acetic acid 14347-78-5, ((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 14970-83-3, 4-Mercapto-1-butanol 15307-86-5, Diclofenac 16051-77-7, Isosorbide 5-mononitrate 18162-48-6, tert-Butyldimethylsilyl chloride 22204-53-1
 22323-82-6, ((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 26159-34-2, (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt 26690-80-2, tert-Butyl N-(2-hydroxyethyl)carbamate 31719-77-4, 3-(Chloromethyl)benzoic acid 42865-19-0, 2-Bromoethyl isocyanate 56552-80-8, (R)-(+)-3-Benzylxy-1,2-propanediol 58479-61-1, tert-Butylchlorodiphenylsilane 86940-98-9, ((4S)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methanol 136088-69-2 646509-51-5, [4-Nitro-1-(nitrooxy)-2-[(nitrooxy)methyl]butan-2-yl]amine 646510-25-0
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 4665-58-1P, [2-(Nitrooxy)ethyl]ammonium nitrate 18226-17-0P, 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethanol 38483-29-3P
 42055-15-2P, 3-(Methylamino)propan-1-ol 49807-74-1P, N-(3-Hydroxypropyl)carboxamide 53164-05-9P, 2-[2-[1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetoxy]acetic acid 54224-25-8P 56834-02-7P, tert-Butyl 2-aminoxyacetate 57561-39-4P
 65141-52-8P, [3-(Nitrooxy)propyl]amine nitrate 75302-98-6P, (tert-Butoxycarbonyl)methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 87426-50-4P, 2-Hydroxyethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 97699-68-8P, 2-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]acetic acid 100502-66-7P, 3-(Nitrooxy)propan-1-ol 104963-92-0P 105566-73-2P, 2-Aminoethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate hydrochloride 136404-13-2P
 139272-68-7P, (tert-Butoxycarbonyl)methyl 2-[2-[(2,6-dichlorophenyl)aminophenyl]acetate 145459-16-1P, Methyl[2-(nitrooxy)ethyl]ammonium nitrate 154504-21-9P, (2S)-2,3-Bis(nitrooxy)propan-1-ol 161469-42-7P, 1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-2,2-dimethyl-1,1-diphenyl-1-silapropane 161469-43-8P, (2S)-3-[(2,2-Dimethyl-1,1-diphenyl-1-silapropyl)oxy]propane-1,2-diol 163385-71-5P, 2-(Nitrooxy)ethyl 4-hydroxybenzoate 163385-76-0P, 2-(Nitrooxy)ethyl 2-hydroxybenzoate 163385-79-3P, 2-(Nitrooxy)ethyl 3-hydroxybenzoate 258278-55-6P, 4-(Nitrooxymethyl)benzoic acid 364057-16-9P 364057-29-4P, 2-[N-(tert-Butoxycarbonyl)-N-methylamino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 364057-30-7P, 2-(Methylamino)ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 382601-32-3P, (2R)-2,3-Bis(nitrooxy)propan-1-ol 385369-72-2P, 2-[(2-Hydroxyethyl)sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-37-7P, 2-[(2-Hydroxyethyl)thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-40-2P 646509-42-4P, 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethyl 2-(6-methoxy-2-naphthyl)propanoate 646509-44-6P
 646509-46-8P, Phosphonomethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-57-1P, [5-(Hydroxymethyl)-1,3-dioxan-5-yl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-61-7P, 3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-65-1P, 3-Hydroxy-2-oxopropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-69-5P 646509-73-1P, 3-Hydroxy-2-(hydroxymethyl)-2-nitropropyl (2S)-2-(6-methoxy-2-

naphthyl)propanoate 646509-77-5P, 2-[(N-(2-Bromoethyl)carbamoyl)oxy]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-82-2P, 3-Hydroxyphenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-86-6P, 4-Hydroxyphenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-90-2P, (tert-Butyloxycarbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-97-9P, Ethyl[2-(nitrooxy)ethyl]ammonium nitrate 646510-00-1P, [N-[(tert-Butoxycarbonyl)methyl]-N-methylcarbamoyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-01-2P 646510-03-4P, [N-[[[(2-Hydroxyethyl)oxy]carbonyl)methyl]-N-methylcarbamoyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-07-8P, [N-[[[(3-Hydroxypropyl)oxy]carbonyl)methyl]-N-methylcarbamoyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-13-6P, [[(2-Hydroxyethyl)oxy]carbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-19-2P, [[2-(2-Hydroxyethylthio)ethyl]oxy]carbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-21-6P, [[2-[(2-Hydroxyethyl)sulfonyl]ethyl]oxy]carbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-32-9P, ((4R)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-35-2P, [(2R)-2,3-Dihydroxy-2-methylpropyl] (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-44-3P, tert-Butyl 2-[[[(2S)-2-(6-methoxy-2-naphthyl)propanoyl]amino]oxy]acetate 646510-46-5P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]oxy]acetic acid 646510-50-1P, 2-[4-(Nitrooxymethyl)phenyl]acetic acid 646510-54-5P 646510-65-8P, Methyl[3-(nitrooxy)propyl]amine 646510-74-9P 646510-77-2P 646510-81-8P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]methyl]-3-hydroxy-2-methylpropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-85-2P, 2-[4-(2-Hydroxyethoxy)phenoxy]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-95-4P 646510-98-7P, N-[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-hydroxybutanamide 646511-03-7P, (2S,3S)-1,4-Bis((1,1,2,2-tetramethyl-1-silapropyl)oxy)butane-2,3-diol 646511-04-8P, (2S,3S)-1,4-Bis[(1,1,2,2-tetramethyl-1-silapropyl)oxy]-2,3-bis(nitrooxy)butane 646511-06-0P, (2S,3S)-2,3-Bis(nitrooxy)butane-1,4-diol 646511-09-3P, 3-[(Nitrooxy)methyl]benzoic acid 646511-11-7P, 2-[(tert-Butoxycarbonyl)amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-15-1P, (2R)-2-Hydroxy-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-27-5P, 2-[(2-Hydroxyethyl)[(4-methylphenyl)sulfonyl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-39-9P, (2S)-1-[(4-Hydroxybutyl)thio]-2-(6-methoxy-2-naphthyl)propan-1-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)
IT 51209-75-7, S-Nitroso-cysteine 56577-02-7, S-Nitroso-N-acetylcysteine 57564-91-7, S-Nitroso-glutathione 79032-48-7, S-Nitroso-N-acetylpenicillamine 122130-63-6, S-Nitroso-captopril 139427-42-2, S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of naproxen-derived nitrosated antiinflammatory compds.)

=>.b wpix
(FILE 'WPIX' ENTERED AT 07:13:50 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 17 NOV 2004 <20041117/UP>
MOST RECENT DERWENT UPDATE: 200474 <200474/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
[<<<](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: [<<<](http://www.thomsonderwent.com/dwpifv)

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF

HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
Derwent Chemistry Resource display fields <<<

=> d all 14

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
 AN 2004-191044 [18] WPIX
 DNC C2004-075275
 TI New nitrosated nonsteroidal compounds are cyclooxygenase inhibitors useful
to treat or reduce e.g. inflammation, pain or fever, gastrointestinal
disorders, inflammatory diseases and gastrointestinal, renal and/or
respiratory toxicity.
 DC B05
 IN EARL, R A; EZAWA, M; FANG, X; GARVEY, D S; GASTON, R D; KHANAPURE, S P;
LETTS, L G; LIN, C; RANATUNGA, R R; RICHARDSON, S K; SCHROEDER, J D;
STEVENSON, C A; WEY, S; LETTS, G L; RANATUNGE, R R
 PA (NITR-N) NITROMED INC
 CYC 102
 PI WO 2004004648 A2 20040115 (200418)* EN 145 A61K000-00
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
 ZM ZW
 US 2004024057 A1 20040205 (200418) A61K031-21 --
 AU 2003247792 A1 20040123 (200459) A61K000-00
 ADT WO 2004004648 A2 WO 2003-US21026 20030703; US 2004024057 A1 Provisional US
2002-393111P 20020703, Provisional US 2002-397979P 20020724, Provisional
US 2002-418353P 20021016, Provisional US 2003-449798P 20030226,
Provisional US 2003-456182P 20030321, US 2003-612014 20030703; AU
2003247792 A1 AU 2003-247792 20030703
 FDT AU 2003247792 A1 Based on WO 2004004648
 PRAI US 2003-456182P 20030321; US 2002-393111P 20020703;
 US 2002-397979P 20020724; US 2002-418353P 20021016;
 US 2003-449798P 20030226; US 2003-612014 20030703
 IC ICM A61K000-00; A61K031-21
 ICS C07C002-00
 AB WO2004004648 A UPAB: 20040316
 NOVELTY - Nitrosated nonsteroidal compounds (A) and their salts are new.
 DETAILED DESCRIPTION - Nitrosated nonsteroidal compounds (A) of
formula Rn-C(Rm)-C(O)-X (I) and RkC(O)-X' (II) and their salts are new.
 Rm = H or lower alkyl;
 Rn = e.g. 4-(thiophen-2-ylcarbonyl)phenyl, 4-(phenylcarbonyl)phenyl,
 4-(1-oxo-isoquinolin-2-yl)phenyl, 5-(4-methylphenylcarbonyl)-N-
 methylpyrrol-2-yl, 4-phenyl-3-fluorophenyl, 5-(phenylcarbonyl)thien-2-yl,
 4-phenoxyphenyl, 6-(methoxy)naphthalen-2-yl or 4,5-diphenyloxazol-2-yl;
 X = e.g. Y-(CR4C4')p-T-(CR4R4')p-ONO2, Y-(CR4R4')q-V-(CR4R4')o-Q'-
 (CR4R4')o-(CH2)-ONO2 or Y-(CR4R4')q-(T)o-(W)q-(CR4R4')o-(CH2)-ONO2;
 R4, R4' = H, lower alkyl, OH, CH2OH, ONO2, NO2 or CH2ONO2;
 CR4 + R4' = cycloalkyl or heterocyclic ring;
 V = C(O)-T, T-C(O), T-C(O)-T or T-C(O)-C(O)-T;
 W = covalent bond or a carbonyl;
 T = O, (S(O)o)o or NRj;
 Rj = H, an alkyl, an aryl, a heterocyclic ring, an alkylcarbonyl, an
 alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an arylsulfinyl, an
 arylsulfonyl, a sulfonamido, a N-alkylsulfonamido, a N,N-
 diarylsulfonamido, a N-arylsulfonamido, a N-alkyl-N-arylsulfonamido, a
 carboxamido or a hydroxyl;
 p = 1-6;
 q = 1-3;
 o = 0-2;
 Y = O or (S);
 B = phenyl or (CH2)o;
 Q' = cycloalkyl group, a heterocyclic ring or an aryl;
 Z = (=O), (=N-OR5), (=N-NR5R'5) or (=CR5R'5);
 M, M' = O- H3N+ (CR4R'4)q-CH2ONO2 or T-(CR4R'4)o-CH2ONO2;
 R5, R5' = H, OH, an alkyl, an aryl, an alkylsulfonyl, an
 arylsulfonyl, a carboxylic ester, an alkylcarbonyl, an arylcarbonyl, a
 carboxamido, an alkoxyalkyl, an alkoxyaryl, a cycloalkyl or heterocyclic
 ring;
 Rk = 2-(2,6-dichloro-3-methylphenylamino)phenyl,
 2-(2,3-dimethylphenylamino)phenyl, 3-(2,4-difluorophenyl)-6-hydroxyphenyl,

2-hydroxyphenyl, 2-(1-oxoethoxy)phenyl, 2-(2-hydroxyphenylcarbonyloxy)phenyl, 2-(3-trifluoromethylphenylamino)phenyl, 2-(3-trifluoromethylphenylamino)pyridin-3-yl, 2,5-dihydroxyphenyl, 5-amino-2-hydroxyphenyl, 2-(2-phenylethylamino)phenyl, 2-(2-methyl-3-trifluoromethylphenylamino)pyridin-3-yl, 2-(2-hydroxyphenylcarbonyloxy)phenyl, 2-(3-chloro-2-methylphenylamino)phenyl or a group of formula (iii)-(vii);
 X' = X or
 With provisos.

NB: Full definitions are given in the DEFINITIONS (Full Definitions) section.

INDEPENDENT CLAIMS are also included for

- (1) a composition (B) comprising (I) and a carrier ; and
- (2) a kit comprising (I) .

ACTIVITY - Antiinflammatory; Analgesic; Antipyretic; Gastrointestinal-Gen.; Laxative; Antiulcer; Tranquilizer; Hemostatic; Antibacterial; Cytostatic; Vulnerary; Cardiovascular-Gen.; Vasotropic; Antiangiogenic; Antiarthritic; Antiasthmatic; Tocolytic; Immunosuppressive; Dermatological; CNS-Gen.; Antiallergic; Antimicrobial; Virucide; Uropathic; Endocrine-Gen.; Nootropic; Neuroprotective; Ophthalmological; Nephrotropic; Cerebroprotective.

(A) were tested for their ability to treat gastric lesions in rats using Kitagawa et al, J. Pharmacol. Exp. Ther., 253:1133-1137 (1990), and Al-Ghamdi et al, J. Int. Med. Res., 19:2242 (1991). The results show that relative gastric lesion activity of (N-methyl-N-(3-(nitrooxy)propyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl)propanoate (Ib) was 0.02 .

MECHANISM OF ACTION - Cyclooxygenase (COX) inhibitor.

USE - (A) are used to treat or reduce inflammation, pain or fever, gastrointestinal disorder (an inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, constipation, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia), facilitates wound healing (ulcer), treat or reverse gastrointestinal, renal and/or respiratory toxicity, treat an inflammatory disease (cardiovascular disorder, reperfusion injury to an ischemic organ, angiogenesis, arthritis, asthma, bronchitis, premature labor, tendinitis, bursitis, an autoimmune disease, an immunological disorder, a skin-related condition, neoplasia(is a brain cancer, a bone cancer, an epithelial cell-derived neoplasia (epithelial carcinoma), a basal cell carcinoma, an adenocarcinoma, a gastrointestinal cancer, a lip cancer, a mouth cancer, an esophageal cancer, a small bowel cancer, a stomach cancer, a colon cancer, a liver cancer, a bladder cancer, a pancreas cancer, an ovary cancer, a cervical cancer, a lung cancer, a breast cancer, a skin cancer, a squamous cell cancer, a basal cell cancer, a prostate cancer, a renal cell carcinoma, a cancerous tumor, a growth, a polyp, an Adenomatous polyp, a familial adenomatous polyposis or a fibrosis resulting from radiation therapy), an inflammatory process in a disease, pulmonary inflammation, a central nervous system disorder(cortical dementia, Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile dementia, alcoholic dementia, senile dementia, memory loss or central nervous system damage resulting from stroke, ischemia or trauma)), allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, a microbial infection, a bacterial-induced inflammation, a viral induced inflammation, a urinary disorder, a urological disorder, endothelial dysfunction, organ deterioration, tissue deterioration, a sexual dysfunction or activation, adhesion and infiltration of neutrophils at the site of inflammation and to treat an ophthalmic disorder.(all claimed).

ADVANTAGE - (I) have good bioavailability, possess potent analgesic and antiinflammatory properties and have unexpected properties for reducing the formation of gastrointestinal lesions (ulcers).

Dwg.0/0

FS	CPI
FA	AB; GI; DCN
MC	CPI: B05-B01E; B05-B01F; B06-H; B07-H; B10-A03; B10-A05; B10-A13D; B10-A17; B10-B01B; B10-B02J; B14-A01; B14-C01; B14-C03; B14-C04; B14-C09; B14-E01; B14-E08; B14-E09; B14-E10; B14-F01; B14-F02; B14-F05; B14-G02; B14-H01; B14-J01; B14-K01; B14-N03; B14-N04; B14-N07; B14-N10; B14-N17; B14-P03; B14-S06

=> b home
 FILE 'HOME' ENTERED AT 07:13:56 ON 18 NOV 2004

=>